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ABSTRACT 
Objective: The objective of the study was to prepare simvastatin transdermal films for the treatment of atherosclerosis and to evaluate the effect of 
concentration of polymer on penetration enhancement. 
Methods: Solvent evaporation technique was employed for the preparation of films and the prepared films were evaluated for various 
physicochemical properties of films such as tensile strength, thickness, surface pH, swellability, drug content, moisture content and folding 
endurance. In vitro drug, release study and release kinetics were also studied. 
Results: Tensile strength ranged from 3.56±0.343 to 4.56±0.12 (N/mm²). The films were of uniform weight. Thickness varied from 0.2±0.3 mm to 
0.2±0.8 mm. Surface pH ranged from 6.6±0.14 to 6.9±0.16. Percentage swellability ranged from12.1±0.36 to 16.3±0.22. Percentage drug content 
ranged from 88.4±0.7% to 90.5±0.6% in all the formulation. Percentage moisture content ranged from 0.864 to 1.03%. Moisture uptake was from 
2.6±0.24 to 2.9±0.072. The folding endurance test gave satisfactory results and F3 formulation showed maximum drug release. 
Conclusion: From the study, it was concluded that out of various formulations, the F3 formulation was found to be the optimum formulation with 
88% drug release at the fourteenth hour. 
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The transdermal film is the most innovative research area in drug 
delivery, and it is aimed to provide a continuous supply of 
medication through the skin into systemic circulation. It has several 
advantages like maintaining constant drug level in blood, fewer side 
effects and improved bioavailability and patient compliance [1] 
being an alternative for the oral route it prevents the 
gastrointestinal pH and enzymatic deactivation of the drug along 
with minimizing the steps involved in the metabolising pathway [2]. 
Simvastatin is an HMG-CoA reductase inhibitor and acts as an anti-
hyper-lipidemic drug and is a structural analogue of HMG-CoA [3]. 
The mechanism of action of HMG-CoA reductase is by usually 70-
75% LDL removing the process of endocytosis. Cholesterol esters 
from LDL molecules are hydrolyzed to free cholesterol in the liver. 
By denovo synthesis liver introduces cholesterol and this pathway 
involves mevalonic acid formation by the enzyme HMG-COA 
reductase [4]. Statins aim at inhibiting this rate-limiting enzyme and 
provide the therapeutic effect. Cholesterol synthesis is decreased 
which leads to increased synthesis of high-affinity LDL receptors 
which results in increased clearance (uptake) of cholesterol-rich 
plasma LDL with subsequent reduction in plasma LDL cholesterol by 
this mechanism. Statins can lower LDL level by 30-50% in maximum 
doses [5]. It is lipophilic in nature, and due to extensive first-pass 
metabolism, the plasma half-life of simvastatin is 2h with an oral 
bioavailability of 5% [6]. To overcome this issue, various new 
techniques employed are transdermal, rectal, buccal and parenteral 
routes of administration [7]. Simvastatin is an ideal candidate for the 
preparation of transdermal films as it has low molecular weight 
(418.56 g/mol), high lipid solubility, low melting point (129 °C), 
effective in low plasma concentration as well as a high degree of 
first-pass metabolism [8]. Solvent evaporation method was used for 
the preparation of films which involves solubilisation of the drug in a 
volatile solvent that is later evaporated. The thermal breakdown of 
drugs can be stopped since organic solvent evaporation occurs at 
low temperature [9]. 
MATERIALS AND METHODS 
Simvastatin was procured from Micro labs, Bangalore, ethyl 
cellulose and methanol were bought from Loba Chemie, Mumbai. 
PEG 4000 and chloroform was procured from Merck specialties pvt 
ltd, Banglore. PVA was procured from Hi media laboratories pvt ltd, 
Mumbai [10]. 
 
Table 1: Composition of transdermal film 
S. No. Ingredients Formula (%w/v) 
F1 F2 F3 
1 Simvastatin 30 30 30 
2 PVA 12% 12% 12% 
3 Ethyl cellulose 2% 2% 2% 
4 PEG 4000 12% 15% 15.5% 
5 Methanol 2.5 2.5 2.5 
6 Chloroform 2.5 2.5 2.5 
 
Preparation of transdermal film 
Solvent evaporation technique was used for the preparation of films 
using petri dish by adding a 12% (w/v) PVA solution and drying for 6 h 
at 60 °C. The backing membrane was produced. The reservoir of the 
drug was then made by adding ethyl cellulose in a mixture of chloroform, 
methanolin (1:1) ratio. PEG 4000 was employed as a plasticizer.  
Later, simvastatin was added and stirred using a magnetic stirrer for 
20 min. The homogenous preparation was cast on a backing 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                                 Vol 10, Issue 5, 2018 
Gowda et al. 
Int J App Pharm, Vol 10, Issue 5, 2018, 235-238 
 
236 
membrane which contains PVA and set aside in a desiccator at room 
temperature for 1 d [11]. 
Physicochemical characterization  
The prepared transdermal films were evaluated for physicochemical 
parameters. 
Physical appearance 
The physical appearance of transdermal films like thickness, colour, 
clarity, flexibility, smoothness, weight and appearance were visually 
inspected as per the standard procedure [12]. 
Thickness 
The transdermal film’s thickness was found out by the use of 
screw gauge (dial thickness gauge 7301, Mitutoyo Corporation, 
kanagawa, Japan) at various part of the film and readings were 
noted [13]. 
Weight variation 
Different films were weighed individually by the use of digital 
balance (shimadzu, Japan) and variation in weight was found out 
and then the average weight was calculated [14]. 
Folding endurance 
Strips were evenly cut and were evaluated by folding the film many 
times on the same spot till it broke. The folding endurance value was 
calculated by noting down the number of times it can be folded at 
the same spot without being broken/cracked [15]. 
Percentage of moisture content 
Films which were prepared were separately weighed and were kept 
for drying in a desiccator which contains activated silica gel. It was 
kept for 24 h. The percentage of moisture content was then 
calculated by using the below equation [16]. 
% Moisture content =
Initial weight− Final weight × 100
Final weight  
Moisture uptake studies 
The films were weighed after 24h of placing it in a desiccator 
containing silica gel and then transferred to another desiccator 
having saturated KCl solution of 85% relative humidity (RH) and 
allowed to attain equilibrium. Later the films were taken out and re-
reweighed. Moisture uptake was further determined by using the 
below equation. 
In a desiccator containing silica gel, the films were kept for 24 h and 
then weighed and moved to another desiccator having saturated KCl 
solution of 85% RH. After attaining equilibrium, the films were taken 
out and weighed. By using the below formula, the moisture uptake 
capacity was calculated [17]. 
Percentage moisture uptake =
Final weight − Initial weight × 100
Initial weight
 
Drug content  
Transdermal films were cut into pieces of a specified area (1 cm2)
Swellability 
 and 
taken in a volumetric flask. Phosphate buffer having pH7.4 was added 
and shaken and kept for 24 h. The drug in solution was determined 
using UV spectrophotometer (shimadzu UV 1800). Absorbance was 
measured at 238 nm, and values were recorded [18]. 
The weighed films were kept in a petri dish consisting of 50 ml of 
phosphate buffer of pH 7.4and the weight was noted down for every 
10 min interval [19]. The degree of swelling was found out using the 
below equation, 
S% =




–weight of film at time t 
0–weight of film at time zero 
S%-percentage swelling 
Surface pH 
The transdermal films were kept for swelling in 0.5 ml of double 
distilled water for 1 h in a glass tube. Combined glass electrode was 
then brought near the film surface and allowed to equilibrate for 1 
min. The surface pH was then measured by using a digital pH meter 
(elico LL120type 003), and the results were noted [20]. 
Flatness study 
This test was carried out to ensure the flat surface and non-
shrinkability of the prepared transdermal films on the progression of 
time. Each film strip was selected and cut from different portions, the 
non-uniformity in flatness was determined by means of measuring the 
variation in length of each strip for % constriction. 100% flatness was 
ensured if constriction was equivalent to 0% [21]. 




l1 is the initial length of each strip 
l2 is the final length of each strip 
Tensile strength 
It was measured using the method of modified analytical two pan 
balance. A film of 6 cm2
Stability studies were conducted based on guidelines of ICH by 
keeping the films at 40±0.5 °C and 75±5%RH for 6 mo. The samples 
were taken during 0,15
 wide was fixed between two clamps on one 
side; weights were added to the pan on another side till the film 
breaks. The weight required to break the film was taken as a 
measure of the tensile strength of the patch [22]. 
Stability study 
th, 30th, 60th, 90th
 
 and 180 d intervals and they 
were analysed [23]. 
RESULTS AND DISCUSSION 
 
Table 2: Evaluation of transdermal patches 
S. No. Properties F1 mean±SD F2 mean±SD F3 mean±SD 
1 Thickness(mm) 0.2±0.3 0.2±0.6 0.2±0.8 
2 Folding endurance  297.0±2.63 298.2±2.01 296.2±1.72 
3 Percentage moisture content 0.91 1.03 0.864 
4 Tensile strength N/mm 3.56±0.343 2 4.56±0.12 4.14±0.234 
5 Moisture uptake 2.6±0.24 2.7±0.32 2.9±0.072 
6 Percentage Swellability 12.1±0.36 15.3±0.41 16.3±0.22 
7 Flatness 100 100 100 
8 Surface pH 6.6±0.14 6.7±0.12 6.9±0.16 
9 Drug content 97.3±0.3 96.6±0.13 98.4±0.32 
mean±SD, n=3 
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Fig. 1: Cumulative % drug release of F1, F2, and F3 
 
Kinetic modelling of drug release 
The pattern of drug release from formulations was analysed using 
BCP software. The release profile of the formulations was fitted into 
release kinetic models like first order, zero order, and higuchi. This 
is shown in table 4. F1 and F3 formulation showed first order release 
with correlation coefficient (R2
 
) value 0.9770 and 0.9919 
respectively. F2 formulation showed zero order release. F3 
formulation was found to show maximum drug release. According to 
S. Parmaret al. the percentage drug release was found to be 80% 
when a novel approach such as spherical agglomerate was made 
[24]. And according to A. M. Pethe et al., a mucoadhesive buccal 
tablet of simvastatin showed 65.96% drug release [25]. The 
transdermal films in the present study showed more than 88% of 
drug release which states that transdermal delivery of simvastatin 
has a higher percentage of drug release when compared to others. 
Table 4: Kinetic modelling of drug release 
Formulation code Zero-order First order Higuchi 
F1 0.9317 0.9770 0.9200 
F2 6.608 0.9945 0.9170 
F3 0.9251 0.9919 0.9197 
 
 
Fig. 2: Transdermal film (F3 formulation) 
 
Prepared transdermal films are of F3 formulation. It showed good 
physicochemical characteristics with good flexibility and maximum 
drug release. It is used in minimizing dose and increased patient 
compliance. According to Bhawana et al. polyethylene glycol used is 
best suited as a plasticizer as compared to others such as glycerine 
since it shows good physicochemical properties like thickness, 
moisture uptake, moisture absorption etc and drug release profile 
[26]. In the studies conducted by Shailesh et al., the transdermal 
films which contained polyethylene glycol were having optimum 
flexibility and were not brittle [27]. According to Prathiket al. 
formulation with ethyl cellulose gave good folding endurance [28] 
and also according to Gajanan et al. with the increase of ethyl 
cellulose in the formulation, the moisture uptake, as well as the 
moisture content, was increased [29]. 
The physicochemical properties of films are depicted in the table 2. 
Tensile strength ranged from 3.56±0.343 to 4.56±0.12 (N/mm²). 
The films were of uniform weight. Thickness varied from 0.2±0.3 to 
0.2±0.8 mm. Surface pH ranged from 6.6±0.14 to 6.9±0.16. 
Percentage swell ability ranged from12.1±0.36 to 16.3±0.22. 
Percentage drug content ranged from 88.4±0.7% to 90.5±0.6% in all 
the formulation. Percentage moisture content ranged from 0.864 to 
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1.03%. Moisture uptake ranged from 2.6±0.24 to 2.9±0.072. The 
folding endurance test gave satisfactory results. F3 formulation 
showed maximum drug release. It was found that as the 
concentration of PEG increased the release of the drug was 
decreased. Hence the incorporation of polyethylene glycol and ethyl 
cellulose in the formulation was responsible for exhibiting good 
physiochemical properties. 
CONCLUSION 
Transdermal films were prepared, and all the formulations showed 
good physicochemical properties and the type of polymer used and 
its concentration was found to affect the drug release. The study 
concluded that as the penetration enhancer’s concentration 
increases the drug permeation was also increased. 
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